Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia

Bone Marrow Transplantation volume 47, pages 872–873 (2012)Cite this article

The mutations of macrophage colony-stimulating factor 1 receptor (FMS)-like tyrosine kinase-3 (FLT3) occur in about one third of adult patients with AML, and determine the poor prognosis of these patients. Recently, some physicians had tested tyrosine kinase inhibitor, sorafenib, for FLT3+ AML patients relapsed after SCT.1, 2, 3, 4, 5

Sorafenib is a multikinase inhibitor active against tyrosine kinase receptors such as vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR3, PDGF receptor, FLT3 and c-kit.6, 7 It has also been reported that sorafenib induces apoptosis in human leukemia cells through the inhibition and downregulation of myeloid cell leukemia-1, a member of the Bcl-2 family.8

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113: 6567–6571.

    Article  CAS  Google Scholar 

  2. Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A et al. Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res 2009; 33: 348–350.

    Article  CAS  Google Scholar 

  3. Choschzick M, Bacher U, Ayuk F, Lebeau A . Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation. J Clin Pathol 2010; 63: 558–561.

    Article  CAS  Google Scholar 

  4. Fesler MJ . Marked bone marrow hypoplasia associated with sorafenib- induced marrow clast clearance in two patients with FLT3-ITD acute myeloid leukemia. Leuk Res 2011; 35: e21–e22.

    Article  Google Scholar 

  5. Sorà F, Chiusolo P, Metafuni E, Bellesi S, Giammarco S, Laurenti L et al. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogeneic stem cell transplantation. Leuk Res 2011; 35: 422–423.

    Article  Google Scholar 

  6. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109.

    Article  CAS  Google Scholar 

  7. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006; 98: 326–334.

    Article  CAS  Google Scholar 

  8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–134.

    Article  CAS  Google Scholar 

  9. Bellmunt J, Eisen T, Fishman M, Quinn D . Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011; 78: 24–32.

    Article  Google Scholar 

  10. Alexandrescu D, McClure R, Farzanmehr H, Dasanu CA . Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 2008; 26: 4047–4048.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. P Chiusolo and E Metafuni: These authors contributed equally to this work

Authors and Affiliations

  1. Department of Hematology, Università Cattolica S. Cuore, Rome, Italy

    P Chiusolo, E Metafuni, S Bellesi, S Giammarco, T Za, L Laurenti, F Sorà, G Leone & S Sica

Authors
  1. P Chiusolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Metafuni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Bellesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Giammarco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Za
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Laurenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Sorà
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Leone
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Sica
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Chiusolo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiusolo, P., Metafuni, E., Bellesi, S. et al. Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia. Bone Marrow Transplant 47, 872–873 (2012). https://doi.org/10.1038/bmt.2011.183

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.183

This article is cited by

Search

Advanced search

Quick links